Amneal (AMRX) insider sale leaves 291,029 shares held directly

Q: What insider transaction did AMRX report in this Form 4?

The filing reports that a director of Amneal Pharmaceuticals, Inc. (AMRX) sold 50,000 shares of Class A common stock in an open-market transaction on 11/17/2025 .

Q: At what price were the AMRX shares sold in this insider transaction?

The shares were sold at a weighted average price of $11.72 per share , with individual trades occurring between $11.70 and $11.75 per share.

Q: How many AMRX shares does the reporting person own after this Form 4 transaction?

Following the sale, the reporting person beneficially owns 291,029 shares of Amneal Class A common stock, held in direct ownership form.

Q: What does the transaction code "S" mean in the AMRX Form 4?

The transaction code "S" in the Form 4 indicates an open-market or private sale of the issuer's equity securities.

Q: Is the AMRX Form 4 transaction part of a Rule 10b5-1 trading plan?

The form includes a checkbox related to Rule 10b5-1(c) trading plans , but the provided content does not indicate that this box was checked or that the sale was made under such a plan.

Q: Does this AMRX Form 4 include any derivative securities activity?

The section for derivative securities is present in the form, but no derivative transactions or holdings are reported in the provided content.

Filing Impact

(High)

Filing Sentiment

(Negative)

Form Type

Rhea-AI Filing Summary

Amneal Pharmaceuticals, Inc. filed a Form 4 showing a share sale by one of its directors. On 11/17/2025, the reporting person sold 50,000 shares of Amneal Class A common stock in an open-market transaction coded "S" for sale. The weighted average sale price was $11.72 per share, with individual trades executed between $11.70 and $11.75 per share.

After this transaction, the reporting person beneficially owns 291,029 shares of Amneal Class A common stock in direct ownership form. The filing notes that full details of the individual trade prices within the reported range are available upon request.

Insider Trade Summary

Net Seller: 50,000 shares

Net Sell 1 txn

Insider Nark Ted C

Role Director

Sold 50,000 shs ($586K)

Type	Security	Shares	Price	Value
Sale	Class A Common Stock	50,000	$11.72	$586K

Holdings After Transaction: Class A Common Stock — 291,029 shares (Direct)

Footnotes (1)

F1. The price included in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.70 to $11.75 per share, inclusive. The Reporting Person undertakes to provide to Amneal Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

Accepted by SEC EDGAR 11/19/2025 - 04:21 PM

FAQ

What insider transaction did AMRX report in this Form 4?

The filing reports that a director of Amneal Pharmaceuticals, Inc. (AMRX) sold 50,000 shares of Class A common stock in an open-market transaction on 11/17/2025.

At what price were the AMRX shares sold in this insider transaction?

The shares were sold at a weighted average price of $11.72 per share, with individual trades occurring between $11.70 and $11.75 per share.

How many AMRX shares does the reporting person own after this Form 4 transaction?

Following the sale, the reporting person beneficially owns 291,029 shares of Amneal Class A common stock, held in direct ownership form.

What does the transaction code "S" mean in the AMRX Form 4?

The transaction code "S" in the Form 4 indicates an open-market or private sale of the issuer's equity securities.

Is the AMRX Form 4 transaction part of a Rule 10b5-1 trading plan?

The form includes a checkbox related to Rule 10b5-1(c) trading plans, but the provided content does not indicate that this box was checked or that the sale was made under such a plan.

Does this AMRX Form 4 include any derivative securities activity?

The section for derivative securities is present in the form, but no derivative transactions or holdings are reported in the provided content.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Nark Ted C

(Last)

(First)

(Middle)

C/O AMNEAL PHARMACEUTICALS, INC.

400 CROSSING BOULEVARD

(Street)

BRIDGEWATER

08807

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
Amneal Pharmaceuticals, Inc. [ AMRX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
11/17/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Class A Common Stock	11/17/2025		S		50,000	D	$11.72⁽¹⁾	291,029	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. The price included in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.70 to $11.75 per share, inclusive. The Reporting Person undertakes to provide to Amneal Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

Remarks:

	/s/ Denis Butkovic, Attorney-in-Fact	11/19/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR